Tsakogiannis Dimitris, Nikolakopoulou Asimina, Zagouri Flora, Stratakos Grigorios, Syrigos Konstantinos, Zografos Eleni, Koulouris Nikolaos, Bletsa Garyfalia
Research Center, Hellenic Anticancer Institute, 10680 Athens, Greece.
1st Department of Respiratory Medicine and Intensive Care Unit, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Medicina (Kaunas). 2021 Nov 1;57(11):1191. doi: 10.3390/medicina57111191.
Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascular integrity. In particular, Angiopoietin-1 activates the endothelial cell (EC)-specific receptor tyrosine kinase,Tie2,which is essential for preserving endothelial quiescence. On the other hand, Angiopoietin-2 acts as an inhibitor of the Angiopoietin-1/Tie2 signaling pathways, thus facilitating the destabilization of quiescent endothelium in cases of inflammation and cancer. Clinical studies have proven that high levels of Angiopoietin-2 indicate the development of non-small-cell lung carcinomas (NSCLC), while high levels of Angiopoietin-2 are strongly related to tumor angiogenesis, lymphangiogenesis, metastasis, and poor prognosis. Interestingly, the association of Angiopoietin-2 levels with the type of surgical approach makes Angiopoietin-2 a valuable factor in selecting the most suitable therapeutic strategy for lung cancer patients. The role of the Angiopoietin-1 and Angiopoietin-4 levels in NSCLC development requires further investigation. The present review focuses on the clinical impact of the Angiopoietin-1, Angiopoietin-2, and Angiopoietin-4 levels in patients diagnosed with NSCLC, emphasizing the interaction between them, and how they affect the development, progression, and metastasis of lung disease. Finally, it estimates the role of angiopoietins levels in the effective therapy of lung cancer patients.
血管生成是一个生物学过程，涉及从现有脉管系统形成新的血管，它在包括肺癌在内的几种癌症的发生和发展中起着重要作用。血管生成素/Tie2配体/受体系统协调血管的完整性。具体而言，血管生成素-1激活内皮细胞（EC）特异性受体酪氨酸激酶Tie2，这对于维持内皮细胞的静止状态至关重要。另一方面，血管生成素-2作为血管生成素-1/Tie2信号通路的抑制剂，因此在炎症和癌症情况下促进静止内皮细胞的不稳定。临床研究已证明，高水平的血管生成素-2表明非小细胞肺癌（NSCLC）的发生，而高水平的血管生成素-2与肿瘤血管生成、淋巴管生成、转移及预后不良密切相关。有趣的是，血管生成素-2水平与手术方式的关联使得血管生成素-2成为为肺癌患者选择最合适治疗策略的一个有价值的因素。血管生成素-1和血管生成素-4水平在NSCLC发生中的作用需要进一步研究。本综述重点关注血管生成素-1、血管生成素-2和血管生成素-4水平对NSCLC患者的临床影响，强调它们之间的相互作用，以及它们如何影响肺部疾病的发生、发展和转移。最后，评估血管生成素水平在肺癌患者有效治疗中的作用。
